Literature DB >> 29081801

Level of Concordance of Pre-, Intra-, and Postoperative Staging in Cervical Cancers (TREYA Study).

M Toure1, A T Bambara2, K K Y Kouassi1, E N Seka1, J M Dia3, I Yao3, O Kimso1, I Adoubi1.   

Abstract

Concomitant radiochemotherapy is the therapeutic standard for locally advanced (Ib2 to IVa stage FIGO) cervical cancer. In the absence of a radiotherapy in many of our Sub-Saharan African countries, surgical resection is the only therapeutic method available in hopes of achieving a definite cure. However, criteria for curative surgery are not always met due to preoperative understaging of most of our patients. In addition to socioeconomic factors, the causes for understaging are numerous. These include the lack of personnel or underqualified personnel and the absence of complete workup to assess the resectability of the tumor, but above all the lack of decision-making through multidisciplinary consultation meetings. This study makes a plea in order to provide our hospitals with qualified personnel and adequate technical platform to allow efficient management of our patients with cervical cancer.

Entities:  

Year:  2017        PMID: 29081801      PMCID: PMC5610798          DOI: 10.1155/2017/8201462

Source DB:  PubMed          Journal:  J Oncol        ISSN: 1687-8450            Impact factor:   4.375


1. Introduction

Surgery with a curative aim treats not only all the tumor mass but also its subclinical extensions (if clinically there are). This standard method is used in cervical cancer of stage IIA and under [1, 2]. Concomitant radiochemotherapy, on the other hand, has been the therapeutic standard for stages IB2 cancers with tumors mass greater than 4 centimeters to stage IVA since the 2000s [3, 4]. Accuracy in staging is a prerequisite for a successful curative surgery. The International Federation of Obstetrics and Gynecology (FIGO) is the most widely used staging system [5, 6]. However, magnetic resonance imaging (MRI) can help with staging [7, 8]. These different methods can cause discrepancies and errors compared to surgical and pathological staging, errors ranging between 17 and 32% for stage IB and between 50 and 64% for the stages IIB and IIIB [9, 10]. In our countries where the technical platform is limited, very few scientific studies have focused on the degree of concordance between pre-, intra-, and postoperative staging. The objective of this study was to evaluate the concordances and discrepancies observed between different staging in a cohort of patients operated on for cervical cancer in Sub-Saharan Africa (Côte d'Ivoire and Burkina Faso).

2. Patients and Method

This retrospective study was carried out jointly in the Oncology and Gynecology Departments of the University hospital of Treichville and the General Surgery Department of the University Hospital of Yalgado Ouédraogo in Abidjan and Ouagadougou, respectively. We identified 78 patients with histologically confirmed squamous cell carcinoma of the uterine cervix diagnosed between June 1, 2015, and May 31, 2016. The patients were operated on in different health care facilities in these countries. We analyzed the patients' characteristics, the conditions in which the clinical examination and the staging were done, the surgical reports, and the results of the histopathological examination.

2.1. Initial Clinical Classification

Patients were examined by one or more medical specialists (gynecologists and/or oncologists) or general practitioners, sometimes under general anesthesia (narcosis). Some examinations (endoscopic and morphological imaging) helped to establish the initial classification according to FIGO (cystoscopy, rectoscopy, pelvic MRI, pelvic CT, and pelvic ultrasound).

2.2. Peroperative Staging

The surgical indication was only given after preoperative staging. In every case, the indication was for an enlarged total colpohysterectomy with iliopelvic lymphadenectomy. A surgical report was systematically written after surgery. It assessed the characteristics of the tumor, the degree of parietal and regional infiltration, the number of lymph nodes removed, the ratio of lymph nodes removed/infiltrated, and the quality of the surgical resection.

2.3. Postoperative Pathology Staging

All surgical specimens were delivered within 48 hours of surgery to the anatomic pathology laboratories to determine macroscopic characteristics, histological type, number of invaded lymph nodes, resection margins, vascular emboli, and histopathological staging. This staging was done according to the pTNM staging system [11, 12] and the pT category allowed defining the FIGO postoperative classification.

2.4. Statistical Analysis

Patient and tumor characteristics were described by the mean, median, and proportion. The concordance between the different stages was evaluated using the Cohen kappa coefficient [13, 14] and represented in Table 1.
Table 1
Kappa coefficientLevel of concordance
>0,81Very good
0,80–0,61Good
0,60–0,41Moderate
0,40–0,21Mediocre
0,20–0,00Poor
<0,001Very poor
Survival was calculated using Kaplan-Meier's method, taking into account the time of participation (in months) and the time between the date of diagnosis and the date of the latest data collected. The follow-up time for patients was 18 months. The latest data were collected from the medical files. For patients who died during hospitalization, the last data recorded were collected from their medical records. Other patients or their relatives were contacted by phone to know their status (“alive” or “deceased”). Survival curves were compared using the Log rank test [15]. The statistical analysis was done using Stata 11 and Epi-Info 3.5.3 software. A threshold of significance of 0.05 was used for analysis.

3. Results

Seventy-eight (78) patients with an average age of 43 years met the inclusion criteria (Table 2).
Table 2

Patients and examination conditions characteristics.

ParametersNumberPercentage (%)
Obesity
 (i) Yes3241,03
 (ii) No4658,97
Circumstance of discovery
 (i) Pain5165,38
 (ii) Metrorrhagia5064,10
 (iii) Leucorrhea4253,85
 (iv) Screening6076,92
Performance status
 (i) 15064,10
 (ii) 22836,90
Nombre of examiners
 (i) 12126,92
 (ii) 23139,74
 (iii) 32633,33
Type of examiner
 (i) Specialist4542,31
 (ii) Generalist3357,69
Examination under narcosis
 (i) Yes4051,28
 (ii) No3848,72
Patient cooperation
 (i) Yes6076,92
 (ii) No1023,08
Pelvic ultrasound
 (i) Yes5975,64
 (ii) No1924,36
Pelvic CT scan
 (i) Yes3848,72
 (ii) No4051,28
MRI
 (i) Yes1924,36
 (ii) No5975,64
Concordance was poor for preoperative versus postoperative staging with Cohen kappa coefficient at 18.07% (Table 3). On the other hand, it was good (Cohen kappa Cohen 79%) for intraoperative versus postoperative staging (Table 5).
Table 3

Clinical staging versus intraoperative staging.

Preoperative staging Intraoperative stagingLevel of underestimation
IAIBIIAIIBIIIAIIIBIVA
IA 1 0000000,0%
IB0 10 4210041,2%
IIA00 10 5412370,6%
IIB001 2 27885,0%
IIIA0000 0 01100%
IIIB00000 1 266,6%
IVA000001 1 50,0%
Table 5

Table of concordance between intraoperative staging and postoperative staging.

Intraoperative stagingPostoperative staging
IaIb1Ib2IIaIIbIIIaIIIbIVaIVbIV
Ia 1 000000000
Ib10 0 00000000
Ib200 10 0000000
IIa000 14 000100
IIb0000 8 01000
IIIa00000 7 0000
IIIb000002 18 001
IVa0000000 6 09
IVb00000000 0 0

∗ refers to the pathology classifications (pT4) without any “a” or “b” specifications.

When studying logistic regression analysis, factors related to discordance were found to be multifactorial. In univaried analysis, pain, metrorrhagia, accidental discovery, number of examiners, type of examiner, examination without narcosis, obesity, and failure to perform a CT scan were the overriding factors. After adjusting other variables, those significantly related to the discrepancy were the type of examiner, the type of morphological examination, and the absence of examination under narcosis (Table 4).
Table 4

Factors related to the clinical versus intraoperative staging discrepancies (logistic regression).

Univariate analysisMultivariate analysis
RCIC 95% p RCIC 95% p
Pain
 No11
 Yes12,57[4,1–38,9]<1044,10,6–26,6NS
Metrorrhagia
 No11
 Yes11,06[3,6–33,6]<1041,10,09–13,1NS
Screening
 No11
 Yes45,3[8,9–231,8]30,5[4,5–207,2] 0,0005
Number of examiners
 111
 20,2[0,02–1,9]0,160,190,02–2,4NS
 30,02[0,002–0,2]<1030,140,007–2,9NS
Type of examiner
 Specialist11
 Generalist9,6[2,5–35,9]1,40,2–11,8NS
Examination under narcosis
 No14,3[3,8–54,1] 10 4 6,5[1,3–31,7] 0,02
 Yes11
Obesity
 No11
 Yes25,9[2,4–33,2] 10 3 6,9[1,2–40,9] 0,03
CT scan
 No6,6[2,1–20,4] 10 3 0,30,05–1,5NS
 Yes11
Regardless of the type of comparison (preoperative versus postoperative, intraoperative versus postoperative), survival at 18 months was significantly greater when there was concordance than when there was not (76.5% versus 27.8%, 48.3% versus 19.8%) (Figures 1 and 2).
Figure 1

Overall survival: preoperative staging versus intraoperative staging (p ≤ 0.001).

Figure 2

Overall survival: intraoperative staging versus postoperative staging (p = 0.0021).

4. Discussion

In Sub-Saharan Africa in general and in Côte d'Ivoire in particular, surgery remains the therapeutic method of reference for cervical cancers [16, 17]. However, this method, in our study for the most part, does not obey the laws of a curative surgery. Indeed, the poor preoperative/intraoperative staging concordance indicates the understaging of our patients. These discrepancies observed in staging could be explained by several factors. They are the inadequacies or the lack of skilled personnel dealing with cervical cancers, the general absence of diagnosis and therapeutic strategy decided during a multidisciplinary team meeting, and, finally, the absence of complete workup to assess the resectability criteria and the operability of the cancer. These various characteristics, which have also been demonstrated in other African series [18, 19], are responsible for frequent postoperative progression with chronic obstructive kidney disease by ureter encasement [18]. Very little data is available in western series due to the paucity of cervical cancers [20]. Moreover, in medicalized countries, the surgical indication is the consequence of an exhaustive pretherapeutic assessment and therefore of care that is similar to the evolutionary stage [21]. However, some western studies have also shown discrepancies ranging from 15 to 20% [9, 10]. The low overall survival rate observed (Figures 1 and 2) is the consequence of these different discrepancies making cervical cancer of bad prognosis [22]. The poor prognosis is related to an inappropriate indication for surgery and thus leading to tumor residue and usually R2 resections.

5. Conclusion

For most of our patients, cervical cancer surgery does not meet the criteria of an excision. The various parameters within the framework of the pretherapeutic assessment were insufficiently realized and resulted in a discrepancy between pre-, intra-, and postoperative staging. The stages in which the majority of our patients were consulted were amenable to concomitant radiochemotherapy. The different survival rates were poor, indicating the somber outcome of cervical cancer for most of our patients. This study advocates for efficient management of cervical cancer, which is a model for prevention and healing. Indeed, its risk factors are well known, its natural history is known, and it is curable when detected early.
  17 in total

1.  FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics.

Authors:  S Pecorelli; J L Benedet; W T Creasman; J H Shepherd
Journal:  Int J Gynaecol Obstet       Date:  1999-01       Impact factor: 3.561

2.  Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology.

Authors:  Corinne Balleyguier; E Sala; T Da Cunha; A Bergman; B Brkljacic; F Danza; R Forstner; B Hamm; R Kubik-Huch; C Lopez; R Manfredi; J McHugo; L Oleaga; K Togashi; K Kinkel
Journal:  Eur Radiol       Date:  2010-11-10       Impact factor: 5.315

3.  Surgical staging and cervical cancer: after 30 years, have we reached a conclusion?

Authors:  David H Moore
Journal:  Cancer       Date:  2008-05-01       Impact factor: 6.860

4.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

5.  A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: potential impact on treatment.

Authors:  K Narayan; R J Hicks; T Jobling; D Bernshaw; A F McKenzie
Journal:  Int J Gynecol Cancer       Date:  2001 Jul-Aug       Impact factor: 3.437

6.  The Role of Surgical Staging for Cervical Cancer.

Authors: 
Journal:  Semin Radiat Oncol       Date:  1994-01       Impact factor: 5.934

7.  Concomitant radiochemotherapy plus surgery in locally advanced cervical cancer: update of clinical outcome and cyclooxygenase-2 as predictor of treatment susceptibility.

Authors:  Mariagrazia Distefano; Gabriella Ferrandina; Daniela Smaniotto; Alessandro Pasquale Margariti; Gianfranco Zannoni; Gabriella Macchia; Riccardo Manfredi; Maria Grazia Mangiacotti; Numa Cellini; Giovanni Scambia
Journal:  Oncology       Date:  2004       Impact factor: 2.935

8.  Estimates of the world-wide prevalence of cancer for 25 sites in the adult population.

Authors:  Paola Pisani; Freddie Bray; D Maxwell Parkin
Journal:  Int J Cancer       Date:  2002-01-01       Impact factor: 7.396

9.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

10.  Concomitant radiochemotherapy of cervical cancer: is it justified to reduce the dosage of cisplatin?

Authors:  Mihály Patyánik; Csaba Nemeskéri; Zsuzsa Póti; Dániel Sinkó; Csilla Pesznyák; Réka Király; Róbert Kois; Arpád Mayer
Journal:  Strahlenther Onkol       Date:  2009-09-12       Impact factor: 3.621

View more
  1 in total

1.  A Retrospective Study of Chemotherapy and 3D-Image-Guided Afterloading Intracavitary Radiotherapy in Locally Advanced Cervical Cancer.

Authors:  Xiaojun Li; Cunlian An; Chunlan Feng; Jieren Sun; Huixiang Lu; Xiaodong Yang; Kaiping Wang; Ruimei Wang
Journal:  J Oncol       Date:  2022-09-30       Impact factor: 4.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.